On April 27, multiple listed companies successively disclosed their first-quarter financial data. Among them, eight firms—Yuanjie Technology, Tianqi Lithium, Hunan Yonergy, Tongguan Copper Foil, Rongjie Co., Ltd., Walvax Biotechnology, Boyun New Materials, and Fuxiang Pharmaceutical—recorded net profit growth exceeding 1000% year-on-year.
Yuanjie Technology's net profit surged by 1153.07% year-on-year in the first quarter. The company achieved operating revenue of 355 million yuan, an increase of 320.94% compared to the same period last year, while net profit attributable to shareholders reached 179 million yuan. The company attributed the performance improvement to increased customer demand, growth in sales of CW light source products for data centers, optimization of its product portfolio, and higher profit margins in data center products. Yuanjie Technology specializes in the research, development, design, and production of high-speed semiconductor chips. As of the close on April 27, its share price stood at 1,418 yuan per share, with a total market capitalization of 121.874 billion yuan.
Tianqi Lithium reported a net profit growth of 1699.12% year-on-year for the first quarter. Operating revenue reached 5.128 billion yuan, up 98.44% year-on-year, while net profit amounted to 1.876 billion yuan. The company cited the development of the new energy industry and rising downstream demand as key factors driving the results, noting that the average selling price of its main lithium products increased significantly compared to the same period last year, leading to substantial growth in revenue and gross profit. Tianqi Lithium is engaged in the development and application of lithium resources and the processing of lithium products, providing sustainable lithium solutions for the transition to clean energy. As of April 27, its share price closed at 73.65 yuan per share, with a total market capitalization of 125.665 billion yuan.
Hunan Yonergy's net profit rose by 1337.77% year-on-year in the first quarter. The company posted operating revenue of 14.965 billion yuan, an increase of 121.31% year-on-year, and net profit of 1.356 billion yuan. The performance improvement was mainly attributed to higher sales volume of phosphate cathode materials and rising product prices driven by increases in the cost of materials such as lithium carbonate. Hunan Yonergy's core business involves the research, development, production, and sale of cathode materials for lithium-ion batteries. As of April 27, its share price closed at 89.87 yuan per share, with a total market capitalization of 75.791 billion yuan.
Tongguan Copper Foil recorded a net profit growth of 2138.17% year-on-year in the first quarter. Operating revenue reached 1.842 billion yuan, up 32.04% year-on-year, while net profit attributable to shareholders was 106 million yuan. The company stated that the performance improvement was primarily due to rising prices of copper foil products. Tongguan Copper Foil is engaged in the research, development, manufacturing, and sale of various high-precision electronic copper foils. As of April 27, its share price closed at 51.31 yuan per share, with a total market capitalization of 42.537 billion yuan.
Rongjie Co., Ltd. reported a net profit increase of 1296.26% year-on-year for the first quarter. Operating revenue totaled 376 million yuan, up 295.77% year-on-year, while net profit attributable to shareholders reached 278 million yuan. The company attributed the results to higher production, sales, and prices of lithium concentrate during the reporting period, which boosted profits from lithium mining and processing, along with increased investment income. Rongjie Co., Ltd. focuses on lithium mining and processing, lithium salt production, and the manufacturing of lithium battery equipment. As of April 27, its share price closed at 90.42 yuan per share, with a total market capitalization of 23.478 billion yuan.
Walvax Biotechnology saw its net profit surge by 4082.41% year-on-year in the first quarter. Operating revenue reached 444 million yuan, down 3.98% year-on-year, while net profit attributable to shareholders was 111 million yuan. The company explained that the performance change was mainly due to a reduction in provisions for bad debts resulting from adjustments in accounting estimates for expected credit losses on accounts receivable, as well as the reversal of previous bad debt provisions. Additionally, research and development expenses decreased as the company's 20-valent pneumococcal polysaccharide conjugate vaccine and COVID-19 variant mRNA vaccine projects entered the capitalization phase, compared to the expense recognition phase in the same period last year. Walvax Biotechnology is a high-tech biopharmaceutical enterprise specializing in the research, development, production, and sale of human vaccines. As of April 27, its share price closed at 11.95 yuan per share, with a total market capitalization of 19.112 billion yuan.
Boyun New Materials reported a net profit growth of 13362.43% year-on-year in the first quarter. Operating revenue reached 380 million yuan, up 125.94% year-on-year, while net profit attributable to shareholders was 132 million yuan. The company stated that the performance improvement was mainly driven by increased sales volume and prices of hard alloy products from its subsidiary Boyun Dongfang, against the backdrop of rising prices of key raw material tungsten carbide, coupled with higher revenue and improved profit margins. Boyun New Materials is primarily engaged in the research, development, production, and sale of aviation wheel brake systems and brake materials, aerospace carbon/carbon composites, high-performance hard alloys, and rare metal powder materials, with products applied in aviation, aerospace, and civilian industries. As of April 27, its share price closed at 20.53 yuan per share, with a total market capitalization of 11.766 billion yuan.
Fuxiang Pharmaceutical recorded a net profit increase of 2633.39% year-on-year in the first quarter. Operating revenue reached 358 million yuan, up 53.09% year-on-year, while net profit attributable to shareholders was 61.1955 million yuan. The company attributed the performance improvement to increased sales volume and prices of products in its new energy segment, rising revenue, and strong market demand driven by the ongoing growth in the new energy sector. Specifically, steady demand for power batteries and a rapid surge in demand for energy storage batteries have boosted upstream lithium battery material requirements, leading to robust performance in the company's lithium battery electrolyte additive business, with core products such as VC and FEC experiencing both volume and price increases. Fuxiang Pharmaceutical's main business involves the research, development, production, and sale of raw materials and intermediates for anti-infective drugs. As of April 27, its share price closed at 19.74 yuan per share, with a total market capitalization of 10.633 billion yuan.
Comments